Cargando…

Therapeutic effects of Crataegus monogyna inhibitors against breast cancer

Breast cancer is a silent killer disorder among women and a serious economic burden in healthcare management. Every 19 s, a woman is diagnosed with breast cancer, and every 74 s, a woman worldwide passes away from the disease. Despite the increase in progressive research, advanced treatment approach...

Descripción completa

Detalles Bibliográficos
Autores principales: Basavarajappa, Girish Meravanige, Rehman, Abdur, Shiroorkar, Predeepkumar Narayanappa, Sreeharsha, Nagaraja, Anwer, Md. Khalid, Aloufi, Bandar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174464/
https://www.ncbi.nlm.nih.gov/pubmed/37180727
http://dx.doi.org/10.3389/fphar.2023.1187079
_version_ 1785040035773415424
author Basavarajappa, Girish Meravanige
Rehman, Abdur
Shiroorkar, Predeepkumar Narayanappa
Sreeharsha, Nagaraja
Anwer, Md. Khalid
Aloufi, Bandar
author_facet Basavarajappa, Girish Meravanige
Rehman, Abdur
Shiroorkar, Predeepkumar Narayanappa
Sreeharsha, Nagaraja
Anwer, Md. Khalid
Aloufi, Bandar
author_sort Basavarajappa, Girish Meravanige
collection PubMed
description Breast cancer is a silent killer disorder among women and a serious economic burden in healthcare management. Every 19 s, a woman is diagnosed with breast cancer, and every 74 s, a woman worldwide passes away from the disease. Despite the increase in progressive research, advanced treatment approaches, and preventive measures, breast cancer rates continue to increase. This study provides a combination of data mining, network pharmacology, and docking analysis that surely could revolutionize cancer treatment by exploiting prestigious phytochemicals. Crataegus monogyna is a small, rounded deciduous tree with glossy, deeply lobed leaves and flat sprays of cream flowers, followed by dark red berries in autumn. Various studies demonstrated that C. monogyna is therapeutically effective against breast cancer. However, the particular molecular mechanism is still unknown. This study is credited for locating bioactive substances, metabolic pathways, and target genes for breast cancer treatment. According to the current investigation, which examined compound–target genes–pathway networks, it was found that the bioactive compounds of C. monogyna may operate as a viable solution against breast cancer by altering the target genes implicated in the disease pathogenesis. The expression level of target genes was analyzed using GSE36295 microarray data. Docking analysis and molecular dynamic simulation studies further strengthened the current findings by validating the effective activity of the bioactive compounds against putative target genes. In summary, we propose that six key compounds, luteolin, apigenin, quercetin, kaempferol, ursolic acid, and oleanolic acid, contributed to the development of breast cancer by affecting the MMP9 and PPARG proteins. Integration of network pharmacology and bioinformatics revealed C. monogyna’s multitarget pharmacological mechanisms against breast cancer. This study provides convincing evidence that C. monogyna might partially alleviate breast cancer and ultimately lays a foundation for further experimental research on the anti-breast cancer activity of C. monogyna.
format Online
Article
Text
id pubmed-10174464
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101744642023-05-12 Therapeutic effects of Crataegus monogyna inhibitors against breast cancer Basavarajappa, Girish Meravanige Rehman, Abdur Shiroorkar, Predeepkumar Narayanappa Sreeharsha, Nagaraja Anwer, Md. Khalid Aloufi, Bandar Front Pharmacol Pharmacology Breast cancer is a silent killer disorder among women and a serious economic burden in healthcare management. Every 19 s, a woman is diagnosed with breast cancer, and every 74 s, a woman worldwide passes away from the disease. Despite the increase in progressive research, advanced treatment approaches, and preventive measures, breast cancer rates continue to increase. This study provides a combination of data mining, network pharmacology, and docking analysis that surely could revolutionize cancer treatment by exploiting prestigious phytochemicals. Crataegus monogyna is a small, rounded deciduous tree with glossy, deeply lobed leaves and flat sprays of cream flowers, followed by dark red berries in autumn. Various studies demonstrated that C. monogyna is therapeutically effective against breast cancer. However, the particular molecular mechanism is still unknown. This study is credited for locating bioactive substances, metabolic pathways, and target genes for breast cancer treatment. According to the current investigation, which examined compound–target genes–pathway networks, it was found that the bioactive compounds of C. monogyna may operate as a viable solution against breast cancer by altering the target genes implicated in the disease pathogenesis. The expression level of target genes was analyzed using GSE36295 microarray data. Docking analysis and molecular dynamic simulation studies further strengthened the current findings by validating the effective activity of the bioactive compounds against putative target genes. In summary, we propose that six key compounds, luteolin, apigenin, quercetin, kaempferol, ursolic acid, and oleanolic acid, contributed to the development of breast cancer by affecting the MMP9 and PPARG proteins. Integration of network pharmacology and bioinformatics revealed C. monogyna’s multitarget pharmacological mechanisms against breast cancer. This study provides convincing evidence that C. monogyna might partially alleviate breast cancer and ultimately lays a foundation for further experimental research on the anti-breast cancer activity of C. monogyna. Frontiers Media S.A. 2023-04-27 /pmc/articles/PMC10174464/ /pubmed/37180727 http://dx.doi.org/10.3389/fphar.2023.1187079 Text en Copyright © 2023 Basavarajappa, Rehman, Shiroorkar, Sreeharsha, Anwer and Aloufi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Basavarajappa, Girish Meravanige
Rehman, Abdur
Shiroorkar, Predeepkumar Narayanappa
Sreeharsha, Nagaraja
Anwer, Md. Khalid
Aloufi, Bandar
Therapeutic effects of Crataegus monogyna inhibitors against breast cancer
title Therapeutic effects of Crataegus monogyna inhibitors against breast cancer
title_full Therapeutic effects of Crataegus monogyna inhibitors against breast cancer
title_fullStr Therapeutic effects of Crataegus monogyna inhibitors against breast cancer
title_full_unstemmed Therapeutic effects of Crataegus monogyna inhibitors against breast cancer
title_short Therapeutic effects of Crataegus monogyna inhibitors against breast cancer
title_sort therapeutic effects of crataegus monogyna inhibitors against breast cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174464/
https://www.ncbi.nlm.nih.gov/pubmed/37180727
http://dx.doi.org/10.3389/fphar.2023.1187079
work_keys_str_mv AT basavarajappagirishmeravanige therapeuticeffectsofcrataegusmonogynainhibitorsagainstbreastcancer
AT rehmanabdur therapeuticeffectsofcrataegusmonogynainhibitorsagainstbreastcancer
AT shiroorkarpredeepkumarnarayanappa therapeuticeffectsofcrataegusmonogynainhibitorsagainstbreastcancer
AT sreeharshanagaraja therapeuticeffectsofcrataegusmonogynainhibitorsagainstbreastcancer
AT anwermdkhalid therapeuticeffectsofcrataegusmonogynainhibitorsagainstbreastcancer
AT aloufibandar therapeuticeffectsofcrataegusmonogynainhibitorsagainstbreastcancer